Archive: 10/01/2014

Regorafenib: Hint of minor added benefit

Regorafenib (trade name: Stivarga) has been approved in Germany since August 2013 for adults with metastatic colorectal cancer in whom previous treatments are no longer effective or for whom these alternatives are not an ...

Mechanism affecting risk of prostate cancer is found

A research group at Biocenter Oulu in Finland has identified a mechanism related to a transcription factor that binds much more strongly onto a particular SNP variant, thereby initiating a genetic programme which enhances ...

page 3 from 6